GSK2269557 ELLIPTA DPI

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

CompletedNCT02691325

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2016-03-14End: 2016-06-05Updated: 2017-04-26

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

CompletedNCT02972905

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2016-10-31End: 2016-12-31Updated: 2017-01-18

Related Papers

Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.

2018-07-2513 citations

Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kδ) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block

2017-09-01